The newly launched kits are available for research purposes only.
Roche, headquartered in Basel, Switzerland, announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits, namely, the AVENIO Tumor Tissue Targeted Kit, Expanded Kit, and Surveillance Kit. The kits enable detect all four classes of mutation in solid tumors and complement Roche’s NGS ctDNA kits for oncology research.
Michael Heuer, CEO, Roche Diagnostics, stated, “With the launch of these innovative assays we are pleased to further empower researchers around the world to continue to advance personalized oncology.” He added, “These three ready-to-use AVENIO Tumor Tissue Analysis Kits enable researchers by providing relevant panel content that cover all four mutation classes to support the wide variety of cases that require genomic profiling, and complement the previously launched AVENIO ctDNA assays for liquid biopsy.”
The kit simplifies research by providing detailed results
The AVENIO Tumor Tissue Analysis Kits are as per the guidelines of National Comprehensive Cancer Network (NCCN) in order to support oncology research. Reportedly, now researchers are allowed to use the AVENIO family of NGS oncology assays to profile the genomic complexities of a variety of solid tumor types, by which, detailed results can be obtained within a period of just five days.
Aadel Chaudhuri, MD, Ph.D., Assistant Professor of Radiation Oncology at Washington University School of Medicine, stated, “Cancer is a highly complex and dynamic disease, so the ability to obtain a detailed and accurate summary of the genomic profile of malignancies is critical. By combining the new AVENIO Tumor Tissue Kits with ctDNA kits containing exactly matched gene content, Roche has created an innovative new system not only for genomic profiling of solid tumors but also to better understand how tumor heterogeneity and tumor burden change over time.”
About the AVENIO Tumor Tissue Analysis Kits
The AVENIO Tumor Tissue Analysis Kits are for research-use-only and not for use in diagnostic procedures. Each kit includes the reagents and software required for laboratories to determine the genomic characteristics of solid tumors through a single DNA workflow. With the AVENIO family of NGS oncology assays, Roche aims to make sequencing simple and accessible for everyday use.
Roche seeks ways to contribute society sustainably
Founded in 1896, Roche is a global leader in pharmaceuticals and diagnostics focused on advancing science to improve human lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare.
The world’s largest biotech company is active in over 100 countries and currently having an employee base of about 94,000 people worldwide. It holds truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. It is also leading in in-vitro diagnostics and tissue-based cancer diagnostics, and front running in diabetes management. Roche seeks better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.
